Effect of male sex and obesity on platelet arachidonic acid in spontaneous hypertensive heart failure rats

Experimental Biology and Medicine

Volumn 229, Issue 7, 2004, Pages 657-664

  Park, Sonhee C ^a   Liu Stratton, Yiwen ^a   Medeiros, Lydia C ^a   McCune, Sylvia A ^a,b   Radin, M Judith ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Myogen Inc   (United States)

Author keywords

Arachidonic acid; Male; Obesity; Platelet; SHHF rats

Indexed keywords

ARACHIDONIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FATTY ACID ANALYSIS; FEMALE; HEART FAILURE; HEART WEIGHT; IMPEDANCE; LEAN BODY WEIGHT; LIPID BLOOD LEVEL; LONGEVITY; MALE; NONHUMAN; OBESITY; RAT; SEX DIFFERENCE; SPONTANEOUSLY HYPERTENSIVE RAT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANIMALIA;

EID: 3042851905     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020422900710     Document Type: Article

References (76)

1. Fike CD, Kaplowitz MR, Pfister SL. Arachidonic acid metabolites and an early stage of pulmonary hypertension in chronically hypoxic newborn pigs. Am J Physiol Lung Cell Mol Physiol 284:L316-323, 2003.
2. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185, 2002.
3. Russo C, Olivieri O, Girelli D, Guarini P. Increased membrane ratios of metabolite to precursor fatty acid in essential hypertension. Hypertension 29:1058-1063, 1997.
4. Simon JA, Fong J, Bernert JT Jr. Serum fatty acids and blood pressure. Hypertension 27:303-307, 1996.
5. Taylor AA. Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. Endocrinol Metab Clin North Am 30:983-997, 2001.
6. Mayes PA. Metabolism of unsaturated fatty acids and eicosanoids. In: Murray RK, Granner DK, Mayes PA, Rodwell VW, Eds. Harper's Biochemistry. Norwalk, CT: Appleton & Lange, pp210-217, 1988.
7. Reilly M, Fitzgerald GA. Cellular activation by thromboxane A2 and other eicosanoids. Eur Heart J 14(Suppl K):88-93, 1993.
8. Schror K, Braun M. Platelets as a source of vasoactive mediators. Stroke 21(Suppl):IV32-35, 1990.
9. Gurbel PA, Gattis WA, Fuzaylov SF, Gaulden L. Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class or clinical outcomes? Am Heart J 143:1068-1075, 2002.
10. Hodgson WC, Sikorski BW, King RG. Cardiovascular sensitivity changes to eicosanoids in rats with experimentally induced diabetes mellitus. Clin Exp Pharmacol Physiol 19:9-15, 1992.
11. Isensee H, Jacob R. Differential effects of various oil diets on the risk of cardiac arrhythmias in rats. J Cardiovasc Risk 1:353-359, 1994.
12. Schror K. The effect of prostaglandins and thromboxane A2 on coronary vessel tone-mechanisms of action and therapeutic implications. Eur Heart J 14(Suppl 1):34-41, 1993.
13. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288:2008-2014, 2002.
14. Haszon I, Papp F, Kovacs J, Bors M, Nemeth I, Bereczki C, Turi S. Platelet aggregation, blood viscosity and serum lipids in hypertensive and obese children. Eur J Pediatr 162:385-390, 2003.
15. Horrobin DF. Abnormal membrane concentrations of 20 and 22-carbon essential fatty acids: a common link between risk factors and coronary and peripheral vascular disease? Prostaglandins Leukot Essent Fatty Acids 53:385-396, 1995.
16. Mandal S, Sarode R, Dash S, Dash RJ. Hyperaggregation of platelets detected by whole blood platelet aggregometry in newly diagnosed noninsulin-dependent diabetes mellitus. Am J Clin Pathol 100:103-107, 1993.
17. Pan DA, Hulbert AJ, Storlien LH. Dietary fats, membrane phospholipids and obesity. J Nutr 124:1555-1565, 1994.
18. Savica V, Bellinghieri G, Barbera CM, Egitto M, Consolo F. The coagulative system in haemodialyzed patients: the relationship between the elderly and hypertrygliceridaemia. Arch It Urol LXIV:155-163, 1992.
19. Srivastava S, Joshi CS, Sethi PP, Agrawal AK, Srivastava SK, Seth PK. Altered platelet functions in non-insulin-dependent diabetes mellitus (NIDDM). Thromb Res 76:451-461, 1994.
20. Vericel E, Calzada C, Chapuy P, Lagarde M. The influence of low intake of n-3 fatty acids on platelets in elderly people. Atherosclerosis 147:187-192, 1999.
21. Vericel, E, Lagarde, M, Dechavanne M, Courpron, P. Increased lipid peroxidation in platelets from elderly people. Thromb Haemost 54:553, 1985.
22. McCune SA, Jenkins JE, Stills HF, Park S, Radin MJ, Jurin RR, Hamlin RE. Renal and heart function in the SHHF/Mcc-cp rat. In: Frontiers in Diabetes Research. Lessons from Animal Diabetes III. London: Smith Gordon, pp397-401, 1990.
23. cp rat model: effects of gender and genotype on age of expression of metabolic complications and congestive heart failure and on response to drug therapy. In: Frontiers in Diabetes Research. Lessons from Animal Diabetes V. London: Smith Gordon, pp255-270, 1995.
24. Radin MJ, Holycross BJ, Hoepf TM, McCune SA. Increased salt sensitivity secondary to leptin resistance in SHHF rats is mediated by endothelin. Mol Cell Biochem 242:57-63, 2003.
25. Radin, MJ, Holycross BJ, Sharkey LC, Shiry L, McCune SA. Gender modulates activation of renin-angiotensin and endothelin systems in hypertension and heart failure. J Appl Physiol 92:935-940, 2002.
26. cp rat. Horm Metab Res 29:214-219, 1997.
27. k) in obese spontaneously hypertensive Koletsky rats (SHROB). J Nutr 128:2299-2306, 1998.
28. Hoversland RC. Onset of obesity and puberty in genetically obese SHHF/Mcc-cp rats. Int J Obesity 16:977-984, 1992.
29. McCune SA, Baker PB, Stills HF. SHHF/Mcc-cp rat: model of obesity, non-insulin dependent diabetes, and congestive heart failure. ILAR News 32:23-27, 1990.
30. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194. 1991.
31. cp rat model: a genetic model of congestive heart failure. In: Mechanisms of Heart Failure. Dordrecht, The Netherlands: Kluwer Academic Publishers, pp91-106, 1995.
32. Holycross BJ, Summers BM, Dunn RB, McCune SA. Plasma renin activity in heart failure-prone SHHF/Mcc-facp rats. Am J Physiol 273:H228-233, 1997.
33. cp rats resist antihypertensive effects of renin-angiotensin system inhibition. Clin Exp Hypertension 23:227-239, 2001.
34. cp rats. Am J Physiol 275:R1968-1976, 1998.
35. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. New Eng J Med 340:1801-1811, 1999.
36. Radin MJ, Jenkins JE, McCune SA, Jurin RR, Hamlin RL. Effects of enalapril and clonidine on glomerular structure, function, and atrial natriuretic peptide receptors in SHHF/Mcc-cp rats. J Cardiovasc Pharmacol 19:464-472, 1992.
37. cp rats. J Cardiovasc Pharmacol 29:726-733, 1997.
38. 2 formation, and fatty acid composition of platelet phospholipids. Am J Clin Nutr 54:351-358, 1991.
39. Folch J, Lee M, Stanley GHS. A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem 226:497-509, 1957.
40. Christie WW. The isolation of lipids from tissues. In: Lipid Analysis (2nd ed.). New York: Pergamon Press, pp17-24, 1982.
41. Nakamura MT, Tang AB, Villanueva J, Halsted CH, Phinney, SD. Selective reduction of delta-6 and delta-5 desaturase activities but not delta-9 desaturase in micro pigs chronically fed ethanol. J Clin Invest 93:450-454, 1994.
42. Morrison WR, Smith LM. Preparation of fatty acid methylesters and dimethyl acetals from lipids with boron fluoride with boron fluoride methanol. J Lipids Res 5:600-608, 1964.
43. Medeiros LC, Liu YW, Park S, Chang PH, Smith AM. Insulin, but not estrogen, correlated with indexes of desaturase function in obese women. Horm Metab Res 27:235-238, 1995.
44. Morita I, Takahashi R, Ito H, Orimo H, Murota S. Increased arachidonic acid content in platelet phospholipids from diabetic patients. Prostaglandins Leukot Med 11:33-41, 1983.
45. Myrup B, Bregengaard C, Petersen LR, Winther K. Platelet aggregation and fatty acid composition of platelets in type 1 diabetes mellitus. Clin Chim Acta 204:251-261, 1991.
46. Phinney SD. Arachidonic acid maldistribution in obesity. Lipids 31(Suppl):S271-S274, 1996.
47. Perez C, Ramiro JM, Campillo JE. Increased arachidonic acid uptake by platelets from insulin-dependent diabetics and diabetic rats. Diabetes Res Clin Pract 7:69-73, 1989.
48. Takahashi R, Morita I, Saito Y, Ito H, Murota S. Increased arachidonic acid incorporation into platelet phospholipids in type 2 (non-insulin-dependent) diabetes. Diabetologia 26:134-137, 1984.
49. Tretjakovs P, Kalnins U, Dabina I, Erglis A, Dinne I, Jurka A, Latkovskis G, Zvaigzne A, Pirags V. Nitric oxide production and arachidonic acid metabolism in platelet membranes of coronary heart disease patients with and without diabetes. Med Prin Pract 12:10-16, 2003.
50. Marra CA, de Alaniz MJT, Brenner RR. Effect of various steroids on the biosynthesis of arachidonic acid in isolated hepatocytes and HTC cells. Lipids 23:1053-1058, 1988.
51. Chen SY, Yu BJ, Liang YQ, Lin WD. Platelet aggregation, platelet cAMP levels and thromboxane B2 synthesis in patients with diabetes mellitus. Chin Med J 103:312-318, 1990.
52. Halushka PV, Mayfield R, Colwell JA. Insulin and arachidonic acid metabolism in diabetes mellitus. Metabolism 34(12 Suppl 1):32-36, 1985.
53. Halushka PV, Mayfield R, Wohltmann HJ, Rogers RC, Goldberg AK, McCoy SA, Loadholt CB, Colwell JA. Increased platelet arachidonic acid metabolism in diabetes mellitus. Diabetes 30(Suppl 2):44-48, 1981.
54. Halushka PV, Rogers RC, Loadholt CB, Wohltman H, Mayfield R, McCoy S, Colwell JA. Increased platelet prostaglandin and thromboxane synthesis in diabetes mellitus. Honn Metab Res Suppl 11:7-11, 1981.
55. Pignatelli P, Lenti L, Sanguigni V, Frati G, Simeoni I, Gazzaniga PP, Pulcinelli FM, Violi F. Camitine inhibits arachidonic acid turnover, platelet function, and oxidative stress. Am J Physiol Heart Circ Physiol 284:H41-H48, 2003.
56. Fitzgerald GA, Catella F, Oates JA. Eicosanoid biosynthesis in human cardiovascular disease. Hum Pathol 18:248-252, 1987.
57. Garcia RLA. The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemiologic data. Clin Exp Rheumatol 19(6 Suppl 25):S41-44, 2001.
58. Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract 50:1-16, 2000.
59. Agren JJ, Hanninen O, Hanninen A, Seppanen K. Dose responses in platelet fatty acid composition, aggregation and prostanoid metabolism during moderate freshwater fish diet. Thromb Res 57:565-575, 1990.
60. Hirai A, Terano T, Hamazaki T, Sajiki J, Kondo S, Ozawa A, Fujita T, Miyamoto T, Tamura Y, Kumagai A. The effects of the oral administration of fish oil concentrate on the release and the metabolism of [14C]arachidonic acid and [14C]eicosapentaenoic acid by human platelets. Thromb Res 28:285-298, 1982.
61. Murray MJ, Zhang T. The incorporation of dietary n-3 polyunsaturated fatty acids into porcine platelet phospholipids and their effects on platelet thromboxane A2 release. Prostaglandins Leukot Essent Fatty Acids 56:223-228, 1997.
62. von Houwelingen AC, Thomgren M, Homstra G, Born GV. Release of thromboxane A2 and beta-thromboglobulin during in-vivo plug fonnation following standardized skin incisions: effect of a moderate fish intake. Thromb Haemost 67:713-717, 1992.
63. Croset M, Vericel E, Rigaud M, Hanss M, Courpron P, Dechavanne M, Lagarde M. Function and tocopherol content of blood platelets from elderly people after low intake of purified eicosapentaenoic acid. Thromb Res 57:1-12, 1990.
64. Driss F, Vericel E, Lagarde M, Dechavanne M, Darcet P. Inhibition of platelet aggregation and thromboxane synthesis after intake of small amount of icosapentaenoic acid. Thromb Res 36:389-396, 1984.
65. Gibney MJ, Bolton-Smith C. The effect of a dietary supplement of n-3 polyunsaturated fat on platelet lipid composition, platelet function and platelet plasma membrane fluidity in healthy volunteers. Br J Nutr 60:5-12, 1988.
66. Liu Y, Medeiros LC. Platelet aggregation, serum and platelet fatty acids in three generations of women. Nutr Res 15:831-842, 1995.
67. Riess H, Merk W, Falkner C, Hiller E. Increased in vitro platelet aggregation in hypertriglyceridemias. Thromb Res 41:281-289, 1986.
68. Aoki I, Aoki N, Kawano K, Shimoyama K, Maki A, Homori M, Yanagisawa A, Yamamoto M, Kawai Y, Ishikawa K. Platelet-dependent thrombin generation in patients with hyperlipidemia. J Am Coll Cardiol 30:91-96, 1997.
69. Konstantinides S, Schafer K, Loskutoff DJ. The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity. Ann N Y Acad Sci 947:134-141, 2001.
70. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for artherothrombotic disease in obesity. J Clinc Invest 108:1533-1540, 2001.
71. Maruyama I, Nakata M, Yamaji K. Effect of leptin in platelet and endothelial cells. Obesity and arterial thrombosis. Ann N Y Acad Sci. 902:315-319, 2000.
72. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 48:426-429, 1999.
73. Ozata M, Avcu F, Dunnus O, Yilmaz I, Ozdemir IC, Yalcin A. Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency. Obes Res 9:627-630, 2001.
74. Gobel BO, Schulte-Gobel A, Weisser B, Glanzer K, Vetter H, Dusing R. Arterial blood pressure. Correlation with erythrocyte count, hematocrit, and hemoglobin concentration. Am J Hypertens 4:14-19, 1991.
75. Saxena S, Wong ET. Heterogeneity of common hematologic parameters among racial, ethnic, and gender subgroups. Arch Pathol Lab Med 114:715-719, 1990.
76. Moore DM. Hematology of the rat. In: Feldman BF, Zinkl JG, Jain NC, Eds. Schalm's Veterinary Hematology. Philadelphia, PA: Lippincott, Williams & Wilkins, pp1210-1218, 2000.